Skip to main content
SpringerLink
Log in

Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?

  • Leukemia (PH Wiernik, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life. However, the potential of cure, especially for patients with advanced or unfavorable disease features, remains elusive. Allogeneic hematopoietic stem cell transplantation, based mainly on the graft vs. myeloma effect, can offer prolonged disease control and probability of cure but unfortunately at the cost of considerable transplant-related toxicity rates. Therefore, the role of allogeneic hematopoietic stem cell transplantation in the treatment of multiple myeloma has been called into question. Recently, several studies, particularly those with long-term follow-up, demonstrated a trend of survival superiority for allografted patients with high-risk disease. These data fuel again the interest in allogeneic stem cell transplantation for selected patients with high-risk multiple myeloma, especially if the high remission rates which can be achieved with the currently used treatment protocols could be long-life sustained through the additional exploitation of the long-lasting anti-multiple myeloma effect, originating from the allograft.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014;28(3):525–42.

    Article  CAS  PubMed  Google Scholar 

  2. Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification and management. Am J Hematol. 2016;91(7):719–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia. 2012;26(1):149–57.

    Article  CAS  PubMed  Google Scholar 

  4. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3.

    Article  PubMed  Google Scholar 

  5. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20.

    Article  CAS  PubMed  Google Scholar 

  6. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kapp M, Stevanović S, Fick K, Tan SM, Loeffler J, Opitz A, et al. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant. 2009;43(5):399–410.

    Article  CAS  PubMed  Google Scholar 

  8. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103(11):4362–4.

    Article  CAS  PubMed  Google Scholar 

  9. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3):1196–8.

    Article  CAS  PubMed  Google Scholar 

  10. Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol. 2009;37(7):791–8.

    Article  PubMed  Google Scholar 

  11. Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, et al. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012;53(8):1525–9.

    Article  CAS  PubMed  Google Scholar 

  12. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24(6):929–36.

    Article  CAS  PubMed  Google Scholar 

  13. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, et al. Progress in allergenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209–16.

    Article  CAS  PubMed  Google Scholar 

  14. Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30(10):2047–54.

    Article  CAS  PubMed  Google Scholar 

  15. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105(11):4532–9.

    Article  CAS  PubMed  Google Scholar 

  16. Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011;117(24):6721–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22):3016–22.

    Article  PubMed  Google Scholar 

  18. Kawamura K, Ikeda T, Hagiwara S, Mori T, Shinagawa A, Nishiwaki K, et al. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. Leuk Lymphoma. 2016;57(9):2077–83.

    Article  PubMed  Google Scholar 

  19. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102(3):593–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015;50(2):204–8.

    Article  CAS  PubMed  Google Scholar 

  23. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30(11):2208–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(6):907–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. • Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37(7):589–97 Prospective randomized phase III study with large series of patients which demonstrated that patient with high-risk multiple myeloma disease have dismal outcome as compared to standard-risk patients even in the era of the modern treatment modalities.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. • Usmani SZ, Ailawadhi S, Sexton R, Hoering A, Lipe B, Hita S, et al. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed high risk multiple myeloma (SWOG 1211). J Clin Oncol. 2020;38(suppl 15):8507. (abstract) A prospective study which showed that patients with multiple myeloma and adverse cytogenetic abnormalities or plasma cell leukemia treated with novel agents had a progression-free survival of less than 3 years.

  27. Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22(6):1250–5.

    Article  CAS  PubMed  Google Scholar 

  28. Roos-Weil D, Moreau P, Avet-Loiseau H, Golmard JL, Kuentz M, Vigouroux S, et al. Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica. 2011;96(10):1504–11.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, et al. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013;48(9):1179–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, et al. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012;87(3):272–6.

    Article  PubMed  PubMed Central  Google Scholar 

  31. •• Yin X, Tang L, Fan F, Jiang Q, Sun C, Hu Y. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. Cancer Cell Int. 2018;18:62 The largest meta-analysis in multiple myeloma patients which demonstrated that allogeneic hematopoietic stem cell transplantation can mitigate the poor outcome of patients with high-risk disease.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474–80.

    Article  CAS  PubMed  Google Scholar 

  33. Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219–25.

    Article  CAS  PubMed  Google Scholar 

  34. Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous–allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(3):398–404.

    Article  PubMed  Google Scholar 

  35. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Asher A, Chanan-Khan AA, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54(3):353–67.

    Article  CAS  PubMed  Google Scholar 

  36. Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.

    Article  CAS  PubMed  Google Scholar 

  37. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015;21(12):2039–51.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Freytes CO, Vesole DH, Le Rademacher J, Zhong X, Gale RP, Kyle RA, et al. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone Marrow Transplant. 2014;49(3):416–21.

    Article  CAS  PubMed  Google Scholar 

  39. De Lavallade H, El-Cheikh J, Faucher C, Fürst S, Stoppa AM, Coso D, et al. Reduced -intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant. 2008;41(11):953–60.

    Article  PubMed  Google Scholar 

  40. Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18(4):617–26.

    Article  CAS  PubMed  Google Scholar 

  41. •• Patriarca F, Bruno B, Einsele H, Spina F, Giaccone L, Montefusco V, et al. Long-term follow-up of a donor versus no-donor comparison in patients with multiple myeloma in first relapse after failing autologous transplantation. Biol Blood Marrow Transplant. 2018;24(2):406–9.Retrospective multicenter study with the largest reported follow-up so far, which demonstrated significant survival benefit (for both PFS and OS) for patients with relapsed MM who have a suitable donor and underwent alloSCT.

    Article  PubMed  Google Scholar 

  42. Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol. 2012;82(2):141–9.

    Article  PubMed  Google Scholar 

  43. Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018;8(3):31.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol. 2011;22(7):1628–35.

    Article  CAS  PubMed  Google Scholar 

  45. Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, et al. Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry. Leuk Res Rep. 2018;10:7–10.

    PubMed  PubMed Central  Google Scholar 

  46. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26(5):1091–7.

    Article  CAS  PubMed  Google Scholar 

  47. Morris C, Iacobelli S, Gahrton G, Garderet L, Drake M, van Biezen A, et al. Has allogeneic transplantation a role in the management of plasma cell leukaemia? A study on behalf of the Myeloma Subcommittee of the Chronic Leukaemia Working Party of the EBMT. Blood. 2011:118: Abstract 2008. https://doi.org/10.1182/blood.V118.21.2008.2008.

  48. Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied NJ, et al. Results of autologous and allogeneic transplantation in patients with primary plasma cell leukemia: a large retrospective analysis of the chronic malignancies working party of the EBMT. Blood. 2018;132 (suppl): Abstract 3425: https://doi.org/10.1182/blood-2018-99-113824.

  49. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780–91.

    Article  PubMed  Google Scholar 

  50. Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, et al. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders Subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. Haematologica. 2017;102(7):e271–4.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019;104(2):370–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol. 2010;148(2):323–31.

    Article  PubMed  Google Scholar 

  53. Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ, et al. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. Haematologica. 2016;101(9):1120–7.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, et al. Outcomes of haploidentical transplantation in patients with relapsed multiple myeloma: an EBMT/CIBMTR report. Biol Blood Marrow Transplant. 2019;25(2):335–42.

    Article  PubMed  Google Scholar 

  55. Sun K, Li M, Sayers TJ, Welniak LA, Murphy WJ. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood. 2008;112(4):1522–129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Caballero-Velazquez T, Lopez-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol. 2013;162(4):474–82.

    Article  CAS  PubMed  Google Scholar 

  57. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica. 2006;91(6):837–9.

    CAS  PubMed  Google Scholar 

  58. Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol. 2006;34(6):770–5.

    Article  PubMed  Google Scholar 

  59. El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93(3):455–8.

    Article  CAS  PubMed  Google Scholar 

  60. Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: results from a phase I/II dose-finding study. Exp Hematol. 2013;41(2):134–42.

    Article  CAS  PubMed  Google Scholar 

  61. Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood. 2011;118(9):2413–9.

    Article  CAS  PubMed  Google Scholar 

  62. Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98(4):934–9.

    Article  CAS  PubMed  Google Scholar 

  64. Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2016;22(2):258–67.

    Article  PubMed  Google Scholar 

  65. Kröger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104(10):3361–3.

    Article  PubMed  Google Scholar 

  66. • Lin Q, Zhao J, Song Y, Liu D. Recent updates on CAR T clinical trials for multiple myeloma. Mol Cancer. 2019;18(1):154.Updates of chimeric antigen receptor (CARTs) T cell therapy in multiple myeloma disease.

    Article  PubMed  PubMed Central  Google Scholar 

  67. • Madduri D, Dhodapkar MV, Lonial S, Jagannath S, Cho HJ. SOHO state of the art updates and next questions: t-cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified t cells and bispecific t-cell-engaging agents. Clin Lymphoma Myeloma Leuk. 2019;19(9):537–44 Updates of T cell therapies in multiple myeloma disease.

    Article  PubMed  Google Scholar 

  68. Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood. 2013;121(2):308–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Koukoulias Κ, Papadopoulou A, Kouimtzidis A, Papayanni PG, Papaloizou A, Sotiropoulos D, et al. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. Br J Haematol. 2021. https://doi.org/10.1111/bjh.17464

Download references

Author information

Authors and Affiliations

  1. Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, 31444, Dammam, Kingdom of Saudi Arabia

    Panayotis Kaloyannidis MD & John Apostolidis MD

Authors
  1. Panayotis Kaloyannidis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Apostolidis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panayotis Kaloyannidis MD.

Ethics declarations

Conflict of Interest

Panayotis Kaloyannidis declares that he has no conflict of interest. John Apostolidis declares that he has no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaloyannidis, P., Apostolidis, J. Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?. Curr. Treat. Options in Oncol. 22, 65 (2021). https://doi.org/10.1007/s11864-021-00864-x

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00864-x

Keywords

Search

Navigation